CRITICAL INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of KemPharm, Inc. and Encourages Investors with
Losses to Contact the Firm
Khang & Khang LLP (the “Firm”) announces that it is investigating claims against KemPharm, Inc. (“KemPharm” or the
“Company”) (Nasdaq: KMPH) concerning possible violations of federal securities laws.
If you purchased shares of KemPharm and want more information, please contact Joon M. Khang, Esquire, of Khang & Khang,
18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.
KemPharm sent a New Drug Application to the U.S. Food and Drug Administration ("FDA") concerning their Apadaz product, intended
to be used as an "abuse-deterrent" opioid that provides the same effectiveness as existing standard-of-care products, but with less
of an addictive experience. However, on May 5, 2016, KemPharm disclosed that the Anesthetic and Analgesic Drug Products Advisory
Committee and the Drug Safety and Risk Management Advisory Committee of the FDA had reviewed and voted strongly against an
abuse-deterrent label for Apadaz. The FDA attributed the vote to an issue with the study design of Apadaz rendering it difficult to
use in assessing the abuse-deterrent effect of the drug.
When this news was released to the investing public, the value of KemPharm dropped, causing investors serious harm.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost
two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.
This press release may constitute Attorney Advertising in some jurisdictions.
Khang & Khang LLP
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170127005614/en/